Top Markets
#1 Brevis Brevis +37.75%
#2 Talus Network Talus Network +30.27%
#3 Tung Tung Tung Sahur Tung Tung Tung Sahur +30.12%
#4 Keep Network Keep Network +29.03%
#5 MemeCore MemeCore +24.60%
#6 Infinity Ground Infinity Ground +22.76%
#7 Allora Allora +20.35%
#8 Starpower Starpower +20.08%
#9 Synapse Synapse +18.93%
#10 屎壳郎 (Dung Beetle) 屎壳郎 (Dung Beetle) +18.73%
Coin of the day
Brevis Brevis
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
IntegraGen SA IntegraGen SA

IntegraGen SA

ALINT
Classifica tra le azioni #19673
IntegraGen SA provides human genome analysis services for academic researcher... IntegraGen SA provides human genome analysis services for academic researcher and life sciences companies in France. Its genomic services include transcriptomics, epigenomics, DNA sequencing, NGS testing for cancer research, and SNP genotyping. The company offers clinical research services, such as clinical grade sequencing and pharmacogenomics; basic and human genetic research; agrigenomic services, including crop and livestock genotyping and high-throughput sequencing for crops and livestock; and microbial genomics services comprising whole-genome microbial sequencing and microbial transcriptomics. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; SIRIUS, a cloud-based software tool that enables researchers to analyze whole genome, whole exome, and gene panel sequencing data; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts. IntegraGen SA was founded in 2000 and is headquartered in Évry, France. IntegraGen SA is a subsidiary of OncoDNA SA.
Prezzo delle azioni
$0.20342561
Capitalizzazione di mercato
$1.34M
Variazione (1 giorno)
-1.44%
Variazione (1 anno)
-65.74%
Paese
FR
Scambia IntegraGen SA (ALINT)

Categoria

Healthcare
Ricavi di IntegraGen SA (ALINT)
Ricavi nel Dec 2025 TTM: $5.89M
Secondo gli ultimi rapporti finanziari di IntegraGen SA, i ricavi attuali dell'azienda (TTM) sono pari a $5.89M. Nel 2023, l'azienda ha registrato ricavi di $13.86M una diminuzione rispetto a i ricavi dell'anno 2022, che erano pari a $14.12M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per IntegraGen SA da 2008 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $5.89M -34.91%
2024 $9.05M -34.70%
2023 $13.86M -1.87%
2022 $14.12M 9.68%
2021 $12.88M 17.75%
2020 $10.94M 17.72%
2019 $9.29M 16.30%
2018 $7.99M 2.28%
2017 $7.81M 18.34%
2016 $6.60M 5.01%
2015 $6.28M -15.26%
2014 $7.42M -0.36%
2013 $7.44M 19.02%
2012 $6.25M 3.91%
2011 $6.02M 36.01%
2010 $4.43M 9.71%
2009 $4.03M 28.07%
2008 $3.15M 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $52.05B 883,391.72%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.26B 207,933.89%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.92B 253,164.55%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 154,074.16%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.29B 106,681.86%
NL